Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 12, 2016

Primary Completion Date

December 10, 2018

Study Completion Date

December 10, 2018

Conditions
Urinary Bladder, OveractiveUrinary Incontinence
Interventions
BIOLOGICAL

onabotulinumtoxinA

OnabotulinumtoxinA (BOTOX®) injection into the bladder.

DRUG

Placebo (saline)

Placebo (saline) injection into the bladder.

Trial Locations (31)

10016

Manhattan Medical Research, New York

11803

Advanced Urology Centers of NY A division of IMP, Plainview

12601

Premier Medical Group of the Hudson Valley, Poughkeepsie

14225

Western New York Urology Associates, Cheektowaga

19004

Urologic Consultants of Southeastern Pennsylvania, Bala-Cynwyd

21117

Chesapeake Urology, Owings Mills

23230

Virginia Urology, Richmond

23235

Virginia Urology Center, Richmond

23462

Urology of Virginia, Virginia Beach

27403

Alliance Urology Specialists, Greensboro

28345

Sandhills Medical Center, Hamlet

28401

PMG Research of Wilmington, Wilmington

32204

East Coast Institute for Research, LLC, Jacksonville

37067

Center for Pelvic Health, Franklin

46062

Urogynecology Associates, Indianapolis

Urology of Indiana, Noblesville

46825

Women's Health Advantage, Fort Wayne

47113

Deaconess Clinic, Inc., Evansville

48084

Michigan Institute of Urology, P.C., Troy

49009

Beyer Research, Kalamazoo

50266

Iowa Clinic, West Des Moines

68114

Adult and Pediatric Urology, Omaha

71106

Regional Urology, Shreveport

75231

Urology Clinics of North Texas, Dallas

80220

Genitourinary Surgical Consultants, Denver

81820

PMG Research of Christie Clinic, Champaign

90048

Tower Urology, Los Angeles

92653

Orange County Urology Associates, Laguna Hills

92868

University of California, Irvine Medical Center, Orange

98043

Integrity Medical Research, LLC, Mountlake Terrace

08837

Premier Urology LLC, Edison

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY

NCT03052764 - Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence | Biotech Hunter | Biotech Hunter